# Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder

> **NCT01309542** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 1403 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Desvenlafaxine Succinate

## Key facts

- **NCT ID:** NCT01309542
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-08
- **Primary completion:** 2006-03
- **Final completion:** 2006-03
- **Target enrollment:** 1403 (ACTUAL)
- **Last updated:** 2011-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01309542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01309542, "Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01309542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*